Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. arch. biol. technol ; 61: e18170788, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-974116

RESUMO

ABSTRACT The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR; EC1.1.1.34) catalyzes the first committed step of isoprenoids biosynthesis in Mevalonate (MVA) pathway. Here we report for the first time the cloning and characterization of a full-length cDNA encoding HMGR from Fritillaria cirrhosa (FcHMGR), a bulbous medicinal plant. The full-length cDNA of FcHMGR was 2072 base pair (bp), containing a 1680-bp open reading frame. Bioinformatical analyses revealed that FcHMGR had HMG CoA-binding domains and two NADPH binding domains, which are required for HMGR activity. Quantitative real-time PCR (qRT-PCR) analysis revealed that FcHMGR expressed high in mature bulbs. A truncated version of FcHMGR protein lacking the N-terminal 249-bp GC rich area was expressed in Escherichia coli. The crude cell lysate containing the recombinant protein showed a better HMGR activity than the control and the relative enzyme activity was calculated to be 1.62 U/mg. The cloning, characterization and functional analysis of FcHMGR gene allowed us to further understand the role of FcHMGR involved in steroidal alkaloid biosynthetic pathway in F. cirrhosa at the molecular level.


Assuntos
Clonagem Molecular , Fritillaria , Meglutol , Biologia Computacional
2.
Rev. Asoc. Méd. Argent ; 110(3): 61-7, 1997. tab, graf
Artigo em Espanhol | LILACS | ID: lil-201830

RESUMO

Las estatinas o inhibidores de la 3-hidroxi 3-metilglutaril coenzima A, son los agentes hipolipemiantes de mayor uso en la actualidad. Su eficacia ha sido demostrada en múltiples estudios clínicos, y dependiendo del tipo de estatina usada y de su dosis, su eficacia en la reducción de LDL-colesterol va desde 13 por ciento hasta 61 por ciento. A través de múltiples estudios, las diferentes estatinas han demostrado ser muy seguras. Los efectos adversos, tales como daño hepático y daño muscular, son de muy baja frecuencia y generalmente reversibles. El uso concomitante de estatinas con otros agentes hipolipemiantes (niacina y resinas) es recomendado como segunda alternativa en el tratamiento de las dislipidemias severas.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Anticolesterolemiantes/uso terapêutico , LDL-Colesterol , Hipercolesterolemia/terapia , Hiperlipidemias/terapia , Meglutol/uso terapêutico , Lovastatina/uso terapêutico , Pravastatina/uso terapêutico , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA